胆囊癌患者胆囊癌组织泛素结合酶E2T蛋白表达及其临床意义探讨*

doi:10.3969/j.issn.1672-5069.2021.04.035

摘要/Abstract

摘要： 目的探讨胆囊癌患者胆囊组织泛素结合酶E2T(UBE2T)蛋白表达及其临床意义。方法 2015年1月～2017年12月收治的胆囊癌患者50例,手术后同时取癌组织和癌旁胆囊组织,另取良性疾病胆囊组织50例,采用Western blot法检测胆囊组织UBE2T蛋白相对表达水平,采用多因素Logistic回归模型分析影响生存的危险因素。结果胆囊癌组织UBE2T蛋白表达量为(2.9±0.4),显著高于癌旁组织(1.5±0.3,P<0.05)或正常胆囊组织(1.7±0.3,P<0.05);不同TNM肿瘤分期、浸润深度、淋巴结转移、远处转移和病理学分级癌组织UBE2T表达差异存在统计学意义(P<0.05);术后中位随访21.0个月,Logrank分析显示,31例UBE2T高表达和19例低表达胆囊癌患者中位生存时间分别为12.0个月和25.0个月(P<0.05);多元Logistic回归分析显示,TNM分期高[OR(95%CI)为1.9(1.5～2.4)]、UBE2T高表达[OR(95%CI)为2.5(2.1～2.9)]、肿瘤浸润程度高[OR(95%CI)为2.3(1.8～3.0)]、淋巴结转移程度高[OR(95%CI)为1.2(1.0～1.8)]、远处转移[OR(95%CI)为2.1(1.7～2.8)]和病理学分级高[OR(95%CI)为1.6(1.3～2.2)]是胆囊癌患者术后生存的危险因素(P<0.05)。结论胆囊癌患者胆囊组织UBE2T蛋白表达显著升高,可能与不良预后相关,有必要进行深入研究。

关键词: 胆囊癌, 泛素结合酶E2T, 预后

Abstract: Objective This study aimed to explore the implication of ubiquitinase E2T (UBE2T) expression in cancerous tissues in patients with gallbladder cancer. Methods 50 patients with gallbladder cancer were included in this study between January 2015 and December 2017. The cancerous and adjacent noncancerous tissues as well as 50 normal gallbladder tissues were collected, and the relative expression of UBE2T was detected by Western bloting. All patients with gallbladder cancer underwent radical tumor resection and followed-up for up to 36 months. The multivariate Logistic regression analysis was applied to predict the risk factors for poor prognosis of patients with gallbladder cancer after operation. Results The relative expression ofUBE2T in cancerous tissue was (2.9±0.4), much higher than (1.5±0.3, P<0.05) in noncancerous or (1.7±0.3, P<0.05) in normal tissues; there were a significant differences as respect to the expression of UBE2T gallbladder between differentTNM stages, invasions, lymph node metastasis, remote metastasis and pathological classification (P<0.05); after 21.0 month follow-up, the Logrank analysis showed that there was a significant difference between 12.0 month survival in 31 patients with high cancerous UBE2T expression and 25.0 month (P<0.05) in 19 patients with low cancerous UBE2T expression; the multivariate Logistic analysis demonstrated that the poor TNM stage [OR(95%CI):1.9(1.5-2.4)], strong cancerous UBE2T expression [OR(95%CI):2.5(2.1-2.9)], tumor invasion [OR(95%CI):2.3(1.8-3.0)], lymph node metastasis [OR(95%CI):1.2(1.0-1.8)], remote metastasis [OR(95%CI):2.1(1.7-2.8)] and poor pathological classification [OR(95%CI): 1.6(1.3-2.2)] were the risk factors for poor prognosis of patients with gallbladder cancer after operation (P<0.05). Conclusion The expression of UBE2T protein in gallbladder tissues of patients with gallbladder cancer is significantly intensified, which might be related to the poor prognosis.

Key words: Gallbladder carcinoma, Ubiquitinase E2T, Prognosis

于涛, 李奎武, 姚琳, 吕武. 胆囊癌患者胆囊癌组织泛素结合酶E2T蛋白表达及其临床意义探讨^*[J]. 实用肝脏病杂志, 2021, 24(4): 593-596.

Yu Tao, Li Kuiwu, Yao Lin, et al. Implication of ubiquitinase E2T expression in cancerous tissues in patients with gallbladder cancer[J]. Journal of Practical Hepatology, 2021, 24(4): 593-596.

参考文献

[1] Sharma A, Sharma KL, Gupta A, et al. Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update. World J Gastroenterol, 2017, 23(22):3978-3998.
[2] Hickman L, Contreras C. Gallbladder cancer: diagnosis, surgical management, and adjuvant therapies. Surg Clin North Am, 2019, 99(2):337-355.
[3] Nemunaitis JM, Brown-GU, Soares H, et al. Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations ofNew Mexico. BMC Cancer, 2018,18(1):665.
[4] Van W S, Fulda S, Dikic I, et al. Visualizing ubiquitination in mammalian cells. EMBO Rep, 2019, 20(2):e46520.
[5] Tecalco CA, Ramírez-Jarquín JO, Cruz-Ramos E. Estrogen receptor alpha and its ubiquitination in breast cancer cells. Curr Drug Targets, 2019, 20(6):690-704.
[6] Wu M, Li X, Huang W, et al. Ubiquitin-conjugating enzyme E2T(UBE2T) promotes colorectal cancer progression by facilitating ubiquitination and degradation of p53. Clin Res Hepatol Gastroenterol, 2020, S2210-7401(20):30188.
[7] Hu W, Xiao L, Cao C, et al. UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3β/β-catenin pathway. Oncotarget, 2016, 7(12):15161-15172.
[8] Liu LP, Yang M, Peng QZ, et al. UBE2T promotes hepatocellular carcinoma cell growth via ubiquitination of p53. Biochem Biophys Res Commun, 2017, 493(1):20-27.
[9] 梁后杰, 秦叔逵, 沈锋, 等. CSCO胆道系统肿瘤诊断治疗专家共识(2019年版). 临床肿瘤学杂志, 2019, 24(9):828-838.
[10] Suzuki E, Bridgewater J. Adjuvant therapy for resected gallbladder cancer. Chin Clin Oncol, 2019, 8(4):39.
[11] Sternby EM, Lundgren L, Cahlin C, et al. Surgical treatment for gallbladder cancer - a systematic literature review. Scand J Gastroenterol, 2017, 52(5):505-514.
[12] 任泰, 李永盛, 耿亚军, 等. 中国2010—2017年胆囊癌治疗模式及预后分析. 中华外科杂志, 2020, 58(9):E008-E008.
[13] Full F, Hahn AS, Großkopf AK, et al. Gammaherpesviral tegument proteins, pml-nuclear bodies and the ubiquitin-proteasome system. Viruses, 2017, 9(10):308.
[14] Böhm S, Szakal B, Herken BW, et al. The buddingyeast ubiquitin protease ubp7 is a novel component involved in s phase progression. J Biol Chem, 2016, 291(9):4442-4452.
[15] Nagakannan P, Iqbal MA, Yeung A, et al. Perturbation of redox balance after thioredoxin reductase deficiency interrupts autophagy-lysosomal degradation pathway and enhances cell death in nutritionally stressed SH-SY5Y cells. Free Radic Biol Med, 2016, 101:53-70.
[16] 周振锋, 马爱军, 潘旭东. 炎症和自噬及泛素化对动脉粥样硬化的作用. 中华老年心脑血管病杂志, 2019, 21(11):1211-1213.
[17] 魏路, 姚峰. 去泛素化酶BRCA1相关蛋白1与肿瘤关系研究进展. 中华实用诊断与治疗杂志, 2018, 32(12):1246-1248.
[18] 盛凤, 沈依萌, 万乔浩, 等. 蛋白激酶B1去类泛素化修饰抑制肝癌的增殖和转移. 中华肿瘤杂志, 2017, 39(11):814-820.
[19] 吴珊, 姚敏. 蛋白质泛素化修饰调控创面愈合机制研究进展. 中华烧伤杂志, 2016, 32(2):119-121.
[20] Cornwell MJ, Thomson GJ, Coates J, et al. Small-molecule inhibition of UBE2T/FANCL-mediated ubiquitylation in the fanconi anemia pathway. ACS Chem Biol, 2019, 14(10):2148-2154.
[21] Lewis TW, Barthelemy JR, Virts EL, et al. Deficiency of the fanconi anemia E2 ubiqitin conjugase UBE2T only partially abrogates alu-mediated recombination in anew model of homology dependent recombination. Nucleic Acids Res, 2019, 47(7):3503-3520.
[22] 潘烽平, 徐言, 徐龙生, 等.泛素结合酶UBE2T在结直肠癌中的表达及其生物学作用. 中华全科医学, 2019,17(2):306-309.
[23] Luo C, Yao Y, Yu Z, et al. UBE2T knockdown inhibits gastric cancer progression. Oncotarget, 2017, 8(20):32639-32654.
[24] Zhang W, Zhang Y, Yang Z, et al. High expression of UBE2T predicts poor prognosis and survival in multiple myeloma. Cancer Gene Ther, 2019, 26(11-12):347-355.
[25] Perez PJ, Corrales SV, Amir E, et al. Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers. Sci Rep, 2017, 7(1):17530.
[26] Zhu X, Li T, Niu X, et al. Identification of UBE2T as an independent prognostic biomarker for gallbladder cancer. Oncol Lett, 2020, 20(4):44.
[27] Gong YQ, Peng D, Ning XH,et al. UBE2T silencing suppresses proliferation and induces cell cycle arrest and apoptosis in bladder cancer cells. Oncol Lett. 2016,12(6):4485-4492.
[28] Wang Y, Leng H, Chen H, et al. Knockdown of UBE2T inhibits osteosarcoma cell proliferation, migration, and invasion by suppressing the PI3K/Akt signaling pathway. Oncol Res,2016, 24(5):361-369.
[29] Liu J, Liu X. UBE2T silencing inhibited non-small cell lung cancer cell proliferation and invasion by suppressing the wnt/β-catenin signaling pathway. Int J Clin Exp Pathol,2017,10(9):9482-9488.

胆囊癌患者胆囊癌组织泛素结合酶E2T蛋白表达及其临床意义探讨^*

Implication of ubiquitinase E2T expression in cancerous tissues in patients with gallbladder cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李变利, 徐丽红. 药物性肝损伤、药物诱导性自身免疫性肝炎和自身免疫性肝炎鉴别诊断研究进展^*[J]. 实用肝脏病杂志, 2021, 24(4): 460-463.
[2]	鲁小龙, 解春宝. IL-6基因多态性对HBV相关ACLF患者短期预后的影响[J]. 实用肝脏病杂志, 2021, 24(4): 516-519.
[3]	金苏素, 颜华东. 血清肾上腺髓质素前体诊断失代偿期肝硬化并发细菌感染及其预测短期预后的价值^*[J]. 实用肝脏病杂志, 2021, 24(4): 528-531.
[4]	张兵, 陈瑞红, 杨威, 徐刚. 肝细胞癌患者血清HSP90α和PIVKA-Ⅱ水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2021, 24(4): 548-551.
[5]	王婷婷, 辛洋, 王娜娜. 肝细胞癌癌组织CBX7和PERK表达及其对手术治疗后患者预后的影响^*[J]. 实用肝脏病杂志, 2021, 24(4): 552-555.
[6]	于哲, 罗婧, 杨永平. 外周血单个核细胞GPSM2水平可能是肝细胞癌预后判断的新型标志物^*[J]. 实用肝脏病杂志, 2021, 24(4): 556-560.
[7]	王梦雨, 杨蕊旭, 范建高. 重视代谢相关脂肪性肝病的特征与预后临床研究^*[J]. 实用肝脏病杂志, 2021, 24(3): 308-311.
[8]	陈晨, 王联发, 王艳, 唐郡, 张骏飞, 黄猛珣, 刘波. 112例新型冠状病毒肺炎患者肝肾功能和心肌酶学变化分析[J]. 实用肝脏病杂志, 2021, 24(3): 351-354.
[9]	刘松涛, 孟庆华, 闾军, 刘梅, 许媛, 周建新, 胡中杰. 淋巴瘤化疗诱发肝衰竭患者临床特点与预后分析[J]. 实用肝脏病杂志, 2021, 24(3): 383-386.
[10]	孔雪杰, 李江, 李昊天, 李绪桐, 郜玉峰. 不同肝病基础的慢加急性肝衰竭患者临床特征和预后评分模型预测效能比较[J]. 实用肝脏病杂志, 2021, 24(3): 387-390.
[11]	苏亚勇, 徐成润, 郭永木, 张惠勇, 刘双平, 陈小兰. 慢加急性乙型肝炎肝衰竭患者死亡危险因素和预后评分模型的构建[J]. 实用肝脏病杂志, 2021, 24(3): 391-394.
[12]	党玲, 贾皑, 王芳. 血清内毒素结合蛋白和sCD163水平预测亚急性肝衰竭患者预后的价值分析[J]. 实用肝脏病杂志, 2021, 24(3): 447-448.
[13]	张维娜, 丁传刚, 赵红英, 李丽, 张曼军, 卢旭. 巨细胞病毒性肝炎患儿血清IFN-γ和IL-18水平变化及其与预后的关系探讨[J]. 实用肝脏病杂志, 2021, 24(2): 208-211.
[14]	王江丽, 裴凌燕, 贺晶晶, 李岚, 袁佳健, 夏莉婷, 崔雯. 血清PTX3和sTWEAK预测失代偿期乙型肝炎肝硬化患者死亡临床价值分析[J]. 实用肝脏病杂志, 2021, 24(2): 236-239.
[15]	刘振, 潘光栋, 周峥, 刘强, 梁越, 黄科团, 郝树青, 杨建青. 肝细胞癌组织COPB2基因水平变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(1): 115-118.